Previous 10 | Next 10 |
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track ...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targ...
The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase II doses of 5mg/m 2 and 7.5mg/m 2 Phase I dose escalation cohorts complete; results to be presented at a medical conference in 1H 2023 Confirmed RECIST re...
Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q3 GAAP EPS of -$0.96 misses by $0.05 . Revenue of $3.04M (-29.8% Y/Y) misses by $2.54M . Cash and cash equivalents of $361.5 million as of September 30, 2022; expected financial runway into 2025 Re...
- Continued clinical progress across pipeline including BT5528 end of Phase I dose escalation update; completion of enrollment in BT5528 initial dose expansion cohorts expected in Q4 - BT8009 clinical update remains on-track for Q4 - Received $10 millio...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT8009, a Nec...
Summary Today, we take our first look at Bicycle Therapeutics, a small developmental biotech concern. The company has some intriguing early stage drug candidates, is well funded and has a couple of partnerships with much larger drug companies. An analysis follows in the paragr...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT8009, a Nec...
Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers ; overall response rates of 22% (including one complete response) and 67%, respectively Emergent safety profile of BT5528 suggests notable differentiation from c...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Morgan S...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-...